ACROBiosystems and Daan Biotherapeutics collaborate on developing immuno-oncology drugs
ACROBiosystems and Daan Biotherapeutics announced the signing of a strategic memorandum of understanding for the development of precision immuno-oncology drugs.
Through this agreement, the two companies plan to establish a multifaceted cooperation framework that encompasses the stable supply of high-performance bio-reagents, technical collaboration for immune-oncology drug development, joint research, and data sharing, thereby accelerating the research, development, and commercialization of precision immunotherapies.
ACROBiosystems is a biotech company providing recombinant proteins, kits, antibodies, and scientific services, offering innovative solutions for drug development. Notably, for the CMC phase of cell and gene therapies, it possesses its own brand, Resilient Supply, which includes high-quality GMP-grade raw materials and quality control (QC) solutions.
It also possesses a GMP production base featuring smart modular design and ISO 9001/GMP certification, producing and supplying products essential for the large-scale manufacturing of biopharmaceuticals, including cytokines, antibodies for cell therapy activation, nucleases, and matrix proteins.
Daan Biotherapeutics is developing a proprietary precision immune modulation platform that selectively activates T cells within the tumor microenvironment. To overcome the toxicity and treatment resistance issues caused by non-specific stimulation—limitations often cited with existing immuno-oncology drugs—the company implements next-generation immune modulation technology that finely controls the T cell activation threshold, aiming to enhance therapeutic efficacy while minimizing side effects.
The company is expanding the indications for this platform to autoimmune and rare diseases, with its lead pipeline having completed preclinical development and is preparing to enter global clinical trials.
“ACROBiosystems is a trusted partner with a quality-focused philosophy and technological innovation capabilities,” Daan Biotherapeutics CEO Cho Byoung-chul said. “This collaboration will not only enhance the efficiency of transitioning from preclinical to clinical development but also accelerate entry into global clinical trials.”
Cho Yong-chan, Country Manager of ACROBiosystems Korea, remarked, “This collaboration with Daan Biotherapeutics, which possesses unparalleled technological expertise in the field of immuno-oncology, will be a highly significant strategic milestone. We expect this partnership to generate positive synergistic effects not only for precision therapeutics but also across the entire Korean biotech industry.”